Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MDMA-assisted psychotherapy for treatment-refractory PTSD in Australia
ACTRN12621001078842Phase 2Completed
- Sponsor
- Edith Cowan University
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of midomafetamine in post-traumatic stress disorder (PTSD), sponsored by Edith Cowan University. Primary endpoints: Adherence to MAPS MDMA-assisted psychotherapy treatment and Change in CAPS-5 Total Severity Score. Started May 2022; status: completed.
02
Drugs
midomafetamine
03
Conditions
post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on ACTRN12621001078842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621001078842.